Physiomics Board Urges Shareholders to Reject Investor-Led Board Overhaul

Physiomics ( (GB:PYC) ) just unveiled an update.

Physiomics has published a circular convening a requisitioned general meeting on 29 April 2026 after shareholder Michael Whitlow, who holds about 12.35% of the company, sought to overhaul the board by appointing three new directors and removing four existing ones, including the CEO and chairman. The board, which had attempted but failed to reach a negotiated compromise offering two non-executive seats to the requisitioning group, unanimously urges shareholders to vote against all the resolutions, arguing the move is premature, potentially disruptive and lacks a credible alternative plan, thereby framing the meeting as a key test of control and governance direction at the AIM-listed firm.

The most recent analyst rating on (GB:PYC) stock is a Sell with a £0.43 price target. To see the full list of analyst forecasts on Physiomics stock, see the GB:PYC Stock Forecast page.

Spark’s Take on PYC Stock

According to Spark, TipRanks’ AI Analyst, PYC is a Neutral.

The score is held back primarily by weak financial performance (ongoing losses and persistent cash burn), partially offset by a low-leverage balance sheet and some improvement in price trend. Valuation is constrained by negative earnings and lack of dividend support.

To see Spark’s full report on PYC stock, click here.

More about Physiomics

Physiomics plc is a UK-based company operating on London Stock Exchange’s AIM market, focused on applying advanced modelling and analytics to support drug development and related life sciences decision-making. The company targets pharmaceutical and biotech clients, positioning itself as a specialist provider of data-driven services to improve clinical and R&D outcomes.

Average Trading Volume: 7,982,061

Technical Sentiment Signal: Sell

Current Market Cap: £2.06M

Learn more about PYC stock on TipRanks’ Stock Analysis page.